Physician profile
Fernando Keller
NPI 1669596201
$25,241.36
in general payments reported to CMS, 2019-2025
49 companies · $2,735 in 2025
The $2,735 reported for 2025 was more than what 81% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,571 · 2020: $2,448 · 2021: $3,207 · 2022: $3,058 · 2023: $4,067 · 2024: $3,156 · 2025: $2,735.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,663 · Education: $295.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,662.75 |
| Education | $294.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $7,813.93 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals Lp | $5,205.14 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,603.32 | 2019-2025 | Ofev, Stiolto Respimat, Jascayd |
| Actelion Pharmaceuticals US, INC. | $1,159.94 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Insmed, INC. | $794.75 | 2019-2025 | Arikayce, Brinsupri |
| Inogen, INC. | $653.67 | 2022-2024 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Philips North America LLC | $581.48 | 2019-2024 | (Ak6) Vest Therapy |
| Regeneron Healthcare Solutions, INC. | $516.14 | 2019-2025 | Dupixent |
| Mylan Specialty L.P. | $507.17 | 2019-2024 | Yupelri |
| United Therapeutics Corporation | $496.49 | 2021-2025 | Tyvaso, Tyvaso, Orenitram |
| Genzyme Corporation | $414.76 | 2019-2025 | |
| Grifols USA, LLC | $401.82 | 2019-2025 | Prolastin-C Liquid |
| Amgen INC. | $396.95 | 2023-2024 | Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $331.24 | 2020-2023 | Glassia |
| Verona Pharma, INC. | $316.98 | 2025 | Ohtuvayre |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fernando Keller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.